Accordingly, resistance to immunotherapy due to TRAIL resistance as a result of hypermethylation of the DR4 and DR5 genes is unlikely in the majority of BCP-ALL cases, at least at disease onset. The gene discussed is TNFRSF10B; the disease is acute lymphoblastic leukemia.